Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | GLA | P06280 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11473415 | 0.93 | KDM4E (0.59) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL11482710 | 0.83 | KDM4E (0.47) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL29276483 | 0.79 | ALDH1A1 (0.61) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL11478777 | 0.78 | ALDH1A1 (0.52) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL9319043 | 0.78 | MAPT (0.59) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL11485687 | 0.78 | MAPT (0.54) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL11251929 | 0.78 | MAPT (0.70) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL9319047 | 0.77 | MAPT (0.70) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL5959032 | 0.77 | MAPT (0.56) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL3139976 | 0.76 | ALDH1A1 (0.71) | MAPTALDH1A1KDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101120046-B | Molded article exhibiting multi-color effects, associated lighting device and resin | ARKEMA FRANCE | 2011-02-23 | — | — | CN | claimed |
| US-20080214706-A1 | Moulded Object Exhibiting a Polychromatic Effect, Associated Light Device and Resin | ARKEMA FRANCE (FR) | 2008-09-04 | — | — | US | claimed |
| EP-1848763-B1 | MOULDED OBJECT EXHIBITING A POLYCHROMATIC EFFECT, ASSOCIATED LIGHT DEVICE AND RESIN | ARKEMA FRANCE (FR) | 2008-04-16 | — | — | EP | claimed |
| CN-101120046-A | Molded article exhibiting multi-color effects, associated lighting device and resin | ARKEMA FRANCE (FR) | 2008-02-06 | — | — | CN | claimed |
| EP-1848763-A1 | MOULDED OBJECT EXHIBITING A POLYCHROMATIC EFFECT, ASSOCIATED LIGHT DEVICE AND RESIN | Arkema France (FR) | 2007-10-31 | — | — | EP | claimed |
| WO-2006087241-A1 | MOULDED OBJECT EXHIBITING A POLYCHROMATIC EFFECT, ASSOCIATED LIGHT DEVICE AND RESIN | ARKEMA FRANCE (FR) | 2006-08-24 | — | — | WO | claimed |
| US-12303582-B2 | Composition for the treatment of nail fungus | OYSTERSHELL NV (BE) | 2025-05-20 | — | — | US | disclosed |
| US-20210299022-A1 | COMPOSITION FOR THE TREATMENT OF NAIL FUNGUS | OYSTERSHELL NV (BE) | 2021-09-30 | — | — | US | disclosed |
| EP-3884933-A1 | COMPOSITION FOR THE TREATMENT OF NAIL FUNGUS | Oystershell NV (BE) | 2021-09-29 | — | — | EP | disclosed |
| CN-101120046-B | Molded article exhibiting multi-color effects, associated lighting device and resin | ARKEMA FRANCE | 2011-02-23 | — | — | CN | disclosed |
| US-7641765-B2 | Applying slurry containing optical brighteners | BASF AKTIENGESELLSCHAFT (DE) | 2010-01-05 | — | — | US | disclosed |
| EP-1438197-B1 | METHOD FOR INCREASING THE WHITENESS OF PAPER BY MEANS OF CATIONIC POLYELECTROLYTES | BASF SE (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080214706-A1 | Moulded Object Exhibiting a Polychromatic Effect, Associated Light Device and Resin | ARKEMA FRANCE (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-1438197-A2 | METHOD FOR INCREASING THE WHITENESS OF PAPER BY MEANS OF CATIONIC POLYELECTROLYTES | BASF AKTIENGESELLSCHAFT (DE) | 2004-07-21 | — | — | EP | disclosed |
| EP-1419298-A1 | METHOD FOR PRODUCTION OF COATED PAPER WITH EXTREME WHITENESS | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003052205-A1 | METHOD FOR PRODUCING PAPER, PAPERBOARD AND CARDBOARD | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003022924-A1 | POLYMER DISPERSIONS COMPRISING VINYLAMIDE COPOLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003021041-A2 | METHOD FOR INCREASING THE WHITENESS OF PAPER BY MEANS OF CATIONIC POLYELECTROLYTES | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020808-A1 | REINFORCEMENT OF THE EFFECT OF OPTICAL BRIGHTENERS BY MEANS OF POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003016624-A1 | METHOD FOR PRODUCTION OF COATED PAPER WITH EXTREME WHITENESS | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303582-B2 | Composition for the treatment of nail fungus | DPM1, PIK3C3, ETF1 | MAPT 183/4885ALDH1A1 181/4885KDM4E 1587/4885 |
| US-20210299022-A1 | COMPOSITION FOR THE TREATMENT OF NAIL FUNGUS | DPM1, PIK3C3, ETF1 | MAPT 183/4885ALDH1A1 181/4885KDM4E 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.